Abstract: The present invention relates to a method for inhibiting high temperature corrosion of corrosion prone metal surfaces by organic acid-containing petroleum streams by providing an effective corrosion-inhibiting amount of an additive aromatic compound tri-substituted with acidic functionalities selected from 5-hydroxyisophthalic acid and 1,3,5-benzenetricarboxylic acid, typically up to 1000 wppm, to the metal surface.

Abstract: A composition of an antioxidant of the formula where R3 is an alkyl group of 2 to 6 carbon atoms, and a dispersant or a detergent, is a useful additive package for lubricant compositions.

Abstract: Disclosed herein is a composition comprising: (A) a lubricant, and (B) at least one compound of the formula:  wherein: each R1 is an independently selected linear alkyl or alkenyl fatty acid group; R2 is a C1 to C3 alkyl group; R3 and R4 are independently selected from the group consisting of hydrogen, alkyl, and aryl; Y is a linear alkyl or alkenyl group; and X is a linear or branched, saturated or unsaturated, divalent hydrocarbon group.

Abstract: Disclosed herein is a composition comprising: (A) a lubricant, and (B) at least one 5-alkyl-2-thione-1,3,4-thiadiazolidine compound of the formula: wherein R1 is a hydrocarbon or functionalized hydrocarbon of from 1 to 30 carbon atoms, R2 and R3 are independently selected from the group consisting of hydrocarbon or functionalized hydrocarbons of from 1 to 30 carbon atoms and hydrogen, and X is oxygen, sulfur or nitrogen.

Abstract: A recording medium comprising a phosphorus-containing fluorocarbon compound is provided. The phosphorus-containing fluorocarbon compound can be used as lubricant or as an additive to a lubricant. The phosphorus-containing fluorocarbon compound can be an esterified aryl phosphorus compound, a salt thereof, or combinations thereof.

Abstract: The present invention relates to the perfumery and flavor industry. It concerns more particularly the use of a compound of formula (I) as perfuming or flavoring ingredient wherein R1 and R2 represent simultaneously or a independently a linear or branched alkyl or alkenyl group containing 1 to 4 carbon atoms, R3 represents a hydrogen, a cycloalkyl or a cycloalkenyl group, possibly substituted, a furanyl group, possibly substituted, a linear or branched alkyl or alkenyl group containing 1 to 12 carbon atoms, possibly substituted, or a linear or branched alkyl or alkenyl group containing 1 to 4 carbon atoms terminated by a carboxyl ester or amide group; and R4 represents a hydrogen or a linear alkyl group containing 1 to 4 carbon atoms. Substituents groups of R3 can be for example C1-C3 alkyl or alkenyl groups, an aromatic ring or C5-C7 cycloalkyl or cycloalkenyl groups, possibly substituted by methyl or ethyl groups.

Abstract: A bar soap preparation having enhanced antibacterial and microbial properties which contains between 0.1 weight % and 95 weight % of at least one anionic surfactant; and at least one acidifying agent present in an amount sufficient to impart a pH of below 5.0. The bar soap provides microbial protection resulting from its rapid microbicidal action.

Abstract: Acidic, hard surface cleaning and disinfecting compositions include a film-forming, organosilicone quaternary ammonium compound providing a protective layer for water and stain repellency

Abstract: A cleaning composition which includes a moderate foaming surfactant and a low foaming surfactant. A synergistic cleaning effect is produced by the surfactants. In a preferred manner, the cleaning composition is a neutral carpet extraction cleaning composition. However it can also be employed as a cleaner for fabrics and hard surfaces.

Abstract: Detergent compositions comprise a water-soluble builder, an enzyme and a polymeric dye transfer inhibiting agent, wherein a means is provided for delaying the release of the enzyme relative to the release of the water-soluble builder to the wash solution. The time to achieve a concentration that is 50% of the ultimate concentration of the water-soluble builder is less than 60 seconds, and the time to achieve a concentration that is 50% of the ultimate concentration of the enzyme is more than 90 seconds.

Abstract: A water soluble container having disposed therein a liquid cleaning composition containing at least one nonionic surfactant, triethanol amine, glycerine or a glycol, an anionic surfactant, a perfume and a fatty acid.

Abstract: The present invention relates to a tablet formed by compressing a particulate material, the particulate material comprising a surfactant and a highly soluble compound, the highly soluble compound having a cohesive effect on the particulate material. In a further aspect of the invention there is provided a method of preparing an aqueous solution of a laundry detergent for use in a washing machine, wherein the aqueous solution of laundry detergent is formed by dissolving in water a tablet formed by compressing a particulate material, the tablet comprising a surfactant and a highly soluble compound, the highly soluble compound having a cohesive effect on the particulate material.

Abstract: Antimicrobial, hard surface cleaning compositions that effectively clean and reduce microorganisms on a surface without resulting in unacceptable filming and/or streaking residue on the surface, generally comprise (a) cationic antimicrobial active; (b) nitrogen-containing polymer; and (c) surfactant. Preferred antimicrobial, hard surface cleaning compositions for use in no-rinse cleaning methods comprise (a) from about 0.001% to about 0.5%, by weight of the composition, of surfactant; (b) cationic antimicrobial active; and (c) nitrogen-containing polymer. Methods of cleaning and reducing microorganisms on hard surfaces comprises contacting the surfaces with such compositions and preferably allowing the compositions to dry on the surface without rinsing the composition from the surface using water or other rinsing solution.

Abstract: Viscosity stable, concentrated, aqueous, liquid fabric softening compositions contain a mixture of biodegradable diester quaternary ammonium softening materials and specific co-active fabric softening materials which include substituted imidazoline compounds and specific quaternary ammonium salts. The compositions have superior stability at both normal and lower temperatures. The best process for preparing such compositions uses a molten premix of the fabric softening materials which is dispersed in an aqueous phase through the use of high shear milling.

Abstract: Novel compounds having the structure (I) where R1 is a lower alkyl group, R2, R3, R4 and R5 is each independently hydrogen or a lower alkyl group, R6 is hydrogen, a lower alkyl group, an alkylidene group or a lower alkenyl group and R7 is hydrogen or a lower alkyl group, have desirable odor properties, possibly of a blackcurrant, green, buchu, cassis nature, and find use in perfumes and perfumed products.

Abstract: This invention provides methods for the preparation of a tissue sealant-treated biomaterial, wherein the tissue sealant used in the method comprises at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, antiproliferatives, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Further provided are the biomaterial prepared therefrom, including vascular grafts.

Abstract: A recombinant DNA molecule comprising a nucleotide sequence (I) which codes for a polypeptide displaying the antigenicity of one, two or more of the Phi p I epitope clones (28, 34, 41, 42, 43, 45, 50, 52, 64, 80, 85, 86, 95, 97, 98, 103, 108, 109, 113, 114), with the amino acid sequences defined in SEQ ID NOS: 5, 7, 9 and 12-28, and preferably being derived from grasses or monocotyledonic plants, or a nucleotide sequence (II) which hybridizes with such a nucleotide sequence (I) under conditions of high stringency. Polypeptides displaying the antigenicity of one, two or more of the Phi p I epitope clones (28, 34, 41, 42, 43, 50, 52, 64, 80, 85, 86, 95, 97, 98, 103, 108, 109, 113, 114). Recombinant expression vectors containing the recombinant molecule and host cells transformed with the vector. Diagnostic methods based on utilizing the polypeptides in immunoassays for humoral antibodies and cellular reactions.

Abstract: A novel antigenic protein which is effective for stimulating antibody production in animals against the sheep scab mite, Psoroptes ovis is disclosed. In cattle, administration of the protein provides protection from infestation by P. ovis by eliciting an immediate-type hypersensitivity response and/or immunizing the animal against P. ovis. The protein is also effective for producing and/or binding antibodies to P. ovis, and may be used as an immunodiagnostic reagent.

Abstract: A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobutyl ether.

Abstract: This invention is directed to a method of treating a burn or healing a wound in a mammal by administering a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide.

Abstract: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.

Abstract: The present invention is based on the surprising and unexpected discovery of new and useful polyamide-alkylator conjugates. As a result of their DNA binding properties, polyamides deliver reactive moieties for covalent reaction at specific DNA sequences and thereby inhibit DNA-protein interactions. Thus, site specific alkylation of DNA is a useful tool to regulate gene expression. In addition to competing with transcription factors or promoters, the conjugates of the present invention will be used to target a gene's coding region. This will allow using synthetic chemistry to create a new class of gene specific “knockout” reagents which will be useful in biological disciplines.

Abstract: The present invention provides peptides which can interact with VEGF and inhibit VEGF interaction with KDR or anti-VEGF antibody thereby inhibiting VEGF mediated angiogenesis or angiogeneis related diseases, polynucleotide encoding the peptides, vectors containing the polynucleotides, pharmaceutical compositions containing the peptides, and methods of inhibiting angiogenesis with the peptides.

Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: The invention provides compositions and methods useful for blocking G protein-mediated signaling events. Compositions provided by the invention relate to carboxy terminal G&agr; peptides, and minigenes which encode such peptides. The invention provides methods of making the minigenes, and methods of using either of the minigenes and the G&agr; carboxy terminal peptides encoded thereby, to block G protein-mediated signaling events. The invention also provides methods of using either of the minigenes and the G&agr; carboxy terminal peptides encoded thereby for the identification of unknown interactions between G proteins and G protein coupled receptors, and for the treatment of pathological disorders associated with G protein-mediated signaling events.

Abstract: The invention relates to novel cationic lipid formulations and use thereof for treatment of cancer, especially in combination with radiation.

Abstract: The present invention provides prophylactic and therapeutic methods of treating the ductal epithelium of an exocrine gland, in particular a mammary gland, for disease, in particular cancer. The methods comprise contacting the ductal epithelium of the exocrine gland with an epithelium-destroying gent, preferably by ductal cannulation, so as to realize a prophylactic or therapeutic effect.

Abstract: The invention concerns the use of fucanes for obtaining medicines for modulating metalloprotease and inhibiting leukocytic elastase. Said medicines help activate collagen synthesis inhibit proliferation of gingival fibroblasts, and activate proliferation of dermal fibroblasts. They are useful in particular for treating periodontal pathologies and dermal lesions.

Abstract: The present invention relates to a composition comprising heparin to be used as a non-thrombogenic surface when in contact with arterial blood flow. It also relates to a device treated on the surface thereof with such a composition.

Abstract: A method for treatment of a vascular or cardiovascular condition or acute coronary syndromes comprises administering an effective amount of a flavone 8-carboxylic acid to a mammal suffering from a vascular or cardiovascular condition or acute coronary syndromes. The flavone 8-carboxylic acid is typically flavone 8-acetic acid. The flavone 8-carboxylic acid can be administered alone or in combination with another agent such as a thrombolytic agent, an antithrombotic agent, an anticoagulant, or an antiplatelet agent. The invention also includes pharmaceutical compositions formulated for the treatment of a vascular or cardiovascular condition or acute coronary syndromes.

Abstract: Provided are a solid preparation which rapidly disintegrates in the oral cavity when taken together with the saliva in the oral cavity or a small amount of water, can be prepared easily and has strength enough to retain its formability upon production or during distribution; and a production process of the solid preparation. Specifically, provided are a solid preparation comprising a low-substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g/ml or greater and a tapped bulk density of 0.60 g/ml or greater, and a sugar and/or sugar alcohol; and a production process of the solid preparation. Also provided are a solid preparation comprising a low-substituted hydroxypropyl cellulose having a volume-average particle size as measured by the dry laser diffraction method of 25 &mgr;m or less which is obtained by pulverizing a low-substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g/ml or greater, a tapped bulk density of 0.

Abstract: The invention concerns derivatives of per-(3,6-anhydro)-cyclodextrin, their preparation, and their use in separating polluting ions, for example in human decontamination. These derivatives correspond to one of the following formula: in which at least one of the R1 groups represents the group —OCH2COOH and the other R1 groups, which may be identical or different, represent a group that corresponds to one of the following formula: OH, OR2, SH, SR2, OCOR2, NH2, NHR2, NR2R3, CONH2, CONHR2, CONR2R3, CN, COOR2, COOH and R2, in which R2 and R3, which may be identical or different, represent an aliphatic or aromatic hydrocarbon group, either saturated or unsaturated, which may include one or several hetero-atoms comprising O, S and N, and n is equal to 6, 7 or 8.

Abstract: Novel active compound combinations of compounds of the formula (I) in which Z, X and A are each as defined in the description with known active compounds and their use for controlling phytopathogenic fungi are described.

Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

Abstract: The present invention provides 3-desoxy vitamin D3 analog esters of the formula: and methods for use and preparation of the same, wherein the dotted line, R1, R2, R3, R4 and L are those defined herein.

Abstract: This invention relates to combination chemotherapy, particularly involving vitamin D or a derivative thereof. In one aspect, the invention provides a method of killing a cell by first administering to the cell vitamin D (or a derivative) and subsequently administering to the cell a cytotoxic agent. Where this strategy is applied to an intact tumor, the present invention provides a method of retarding the growth of the tumor by first administering vitamin D (or a derivative) to the tumor and subsequently administering the cytotoxic agent. A further aspect of the invention concerns a method of treating prostate cancer within a patient by co-administration of vitamin D (or a derivative) and a glucocorticoid to the patient. In yet a further aspect, the invention provides an improved method of treating a patient with vitamin-D involving the adjunctive administration of zoledronate.

Abstract: Compounds of formula (I) compounds of formula (II) compounds of formula (III) and compounds of formula (IV) or pharmaceutically acceptable salts thereof are useful as H3 receptor antagonists. Processes to make the compounds and methods of treatment using the compounds are also disclosed.

Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Abstract: Matrix metalloproteinase inhibitors are tricyclic substituted cyclic sulfonamides of the formula or a pharmaceutically acceptable salt thereof wherein R1 and R2 include hydrogen, alkyl, and substituted alkyl; R3 and R4 include hydrogen, halo, and alkyl; X is OH or NHOH, V is O, S, SO2, NR5, or CH2, R5 is a hydrogen or alkyl, and Z is (CH2)n, wherein n is an integer from 0 to 2.

Abstract: There is provided compounds of formula I, wherein R1, R2, R3, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Abstract: Compounds of the formula I in which X, Y, Z, R1, R2, R3, R4, R5, R7, R8, R11, m and n have the meanings stated in claim 1, and their physiologically acceptable salts can be used as integrin inhibitors, in particular for the prophylaxis and treatment of circulatory disorders, for thrombosis, myocardial infarct, coronary heart disease, arteriosclerosis, osteoporosis, for pathological processes maintained or propagated by angiogenesis, and in tumour therapy.

Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

Abstract: There is provided an aminophenoxyacetic acid derivative of the following formula (I): wherein, R1, R2, R3 and R4 are, independent from each other, alkoxy group, alkyl group or aryl group, etc.; E1 and E2 are oxygen atom, sulfur atom, etc.; n is 0 to 5; X and Y are alkylene group, cycloalkylen group, or alkenylen group; Q is phenyl group which may be substituted or benzoyl group, etc, or a pharmaceutically acceptable salt thereof. These compounds have neuroprotective effects by inducing calbindin D28Kd, one of Ca2+-binding proteins.

Abstract: This invention is directed to poly-hydroxylated monocyclic N-heterocyclic derivatives selected from the following formulae: wherein Z1, Z2, R1, R2, R3, R4, R5, R6, and R7 are defined herein. These compounds are useful as anti-coagulants.

Abstract: Use of compounds modulating P2 purinoceptors, in particular antagonists such as Basilen Blue E-3G (Reactive Blue 2), for the prevention of the damages due to global cerebral ischemia and ischemia-reperfusion. Said compounds reduce the mortality in case of global cerebral ischemia as well as the neuronal damage of the hippocampus.

Abstract: Antirheumatic agent containing as an active ingredient a compound resented by the following general formula (II):

Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.

Abstract: 6-(2-Trifluoromethyl-phenyl)-triazolopyrimidines of formula I in which R1 and R2 independently denote hydrogen or alkyl, alkenyl, alkynyl, alkadienyl, or haloalkyl, cycloalkyl, bicycloalkyl, phenyl, naphthyl, or 5- or 6-membered heterocyclyl, containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom, or 5- or 6-membered heteroaryl, containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom, or where R1 and R2 radicals may be unsubstituted or substituted as defined in the specification; or R1 and R2 together with the interjacent nitrogen atom represents a 5- or 6-membered heterocyclic ring, containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom, which may be substituted as defined in the specification; R3 is hydrogen, halogen, alkyl, alkoxy and haloalkyl; and X is halogen; processes and intermediates for preparing these compounds, compositions comprising them a

Abstract: The present invention relates to the synthesis of a novel class of pyrazolo[3,4-d]pyrimidin-4-ones of formula (I), alternatively represented by the tautomer (II): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cyclin dependent kinase 1-8 and their regulatory subunits know as cyclins A-H, K, N, and T. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

Abstract: This invention relates to compounds which are generally alpha-1B adrenergic receptor antagonists and which are represented by Formula (I): wherein R′, R″, R1, R2, m, n, and A are as defined in the specification, or acceptable prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.